Skip to main content
Livermore
Livermore
ZHEN

Bristol Myers Squibb Co

BMY
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0000014272

In the last 90 days, Bristol Myers Squibb Co insiders filed 0 open-market purchases and 2 sales; 2,529 institutions reported holding it in 13F filings for Q2 2026, worth $96.7B in total; no superinvestor holds it.

Other share classesCELG.RI

Superinvestors holding BMY, Q2 2026

See all superinvestors

No superinvestor reported holding BMY in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of BMY each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q2 2025

    0 superinvestors holding at quarter end

    Sold out
    Harris Associates (Oakmark)

  2. Q1 2025

    1 superinvestor holding at quarter end

    New
    Harris Associates (Oakmark)

  3. Q1 2022

    0 superinvestors holding at quarter end

    Sold out
    Berkshire Hathaway, Viking Global Investors

  4. Q4 2021

    2 superinvestors holding at quarter end

    Reduced
    Berkshire Hathaway (−76.4%), Viking Global Investors (−74.1%)

  5. Q3 2021

    2 superinvestors holding at quarter end

    Reduced
    Berkshire Hathaway (−16.2%), Viking Global Investors (−37.9%)
    Sold out
    ARK Invest

  6. Q2 2021

    3 superinvestors holding at quarter end

    Added
    Viking Global Investors (+117.8%)
    Reduced
    Berkshire Hathaway (−15.3%), ARK Invest (−12.7%)
    Sold out
    Maverick Capital